BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: June 9, 2003, 05:35:57 ; Search time 42 Seconds
(without alignments)
1196.083 Million cell updates/sec

Title: US-10-091-628-2
Perfect score: 1979
Sequence: 1 MRANCSSSSACPANSSEEEL.....PGPMDCHRALEPVGHITSCE 377

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

ched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_101002:*
1: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	884	44.7	348	16	AAR77224	Hamster ileal/rena
2	860.5	43.5	348	16	AAR77225	Human ileal/renal
3	386.5	19.5	491	23	AAE13283	Human transporters
4	363.5	18.4	225	23	AAE21252	Human gene 8 encod
5	354.5	17.9	454	22	ABG00575	Novel human diagno
6	318.5	16.1	207	23	AAE21253	Human gene 8 encod
7	284	14.4	338	23	ABB91897	Herbicidally activ
8	280	14.1	356	21	AAG22453	Arabidopsis thalia
9	273	13.8	423	21	AAG48158	Arabidopsis thalia
10	268.5	13.6	335	22	AAG91138	C glutamicum prote
11	266	13.4	455	22	ABB70896	Drosophila melanog
12	265.5	13.4	196	23	ABG64873	Human albumin fusi
13	265.5	13.4	196	23	AAE21198	Human gene 8 encod
14	264.5	13.4	324	22	AAG92300	C glutamicum prote
15	264	13.3	271	21	AAG22454	Arabidopsis thalia
16	257	13.0	285	21	AAG48159	Arabidopsis thalia
17	255	12.9	268	21	AAG22455	Arabidopsis thalia
18	250	12.6	607	22	ABG00574	Novel human diagno
19	248	12.5	282	21	AAG48160	Arabidopsis thalia
20	240	12.1	288	21	AAG17449	Arabidopsis thalia
21	240	12.1	288	21	AAG42824	Arabidopsis thalia
22	240	12.1	401	21	AAG17448	Arabidopsis thalia
23	240	12.1	401	21	AAG42823	Arabidopsis thalia
24	239	12.1	454	22	ABB64740	Drosophila melanog
25	237.5	12.0	267	21	AAG17450	Arabidopsis thalia
26	237.5	12.0	267	21	AAG42825	Arabidopsis thalia
27	173	8.7	337	21	AAG04229	Arabidopsis thalia
28	173	8.7	339	21	AAG40109	Arabidopsis thalia
29	173	8.7	409	21	AAG04228	Arabidopsis thalia
30	173	8.7	411	21	AAG40108	Arabidopsis thalia
31	173	8.7	415	21	AAG04227	Arabidopsis thalia
32	173	8.7	417	21	AAG40107	Arabidopsis thalia
33	171	8.6	460	23	ABB93051	Herbicidally activ
34	156	7.9	379	23	ABB92907	Herbicidally activ
35	150	7.6	342	21	AAG21862	Arabidopsis thalia
36	150	7.6	342	21	AAG51196	Arabidopsis thalia
37	150	7.6	342	21	AAG51219	Arabidopsis thalia
38	150	7.6	354	21	AAG21861	Arabidopsis thalia
39	150	7.6	354	21	AAG51195	Arabidopsis thalia
40	150	7.6	354	21	AAG51218	Arabidopsis thalia
41	150	7.6	431	21	AAG21860	Arabidopsis thalia
42	150	7.6	431	21	AAG51194	Arabidopsis thalia
43	150	7.6	431	21	AAG51217	Arabidopsis thalia
44	142	7.2	65	22	AAM65663	Human brain expres
45	129.5	6.5	394	23	ABB92435	Herbicidally activ

ALIGNMENTS

RESULT 1
AAR77224
ID AAR77224 standard; Protein; 348 AA.
XX
AC AAR77224;
XX
DT 17-DEC-1995 (first entry)
XX
DE Hamster ileal/renal bile acid cotransporter.
XX
KW Ileal/renal bile acid cotransporter; therapeutic; gene therapy;
KW diagnostic.
XX
OS Cricetulus griseus.
XX
PN WO9517905-A1.
XX
PD 06-JUL-1995.
XX
PF 29-DEC-1994; 94WO-US14431.
XX
PR 29-DEC-1993; 93US-0176126.
XX
PA (UYWA-) UNIV WAKE FOREST.
XX
PI Dawson PA;
XX
DR WPI; 1995-246189/32.
DR N-PSDB; AAQ91108.
XX
PT Hamster and human ileal and bile acid transport DNA and protein -
PT useful in treatment of e.g. hypercholesterolaemia, diabetes and
PT various digestive diseases, and in gene therapy to restore bile acid

PT uptake activity.
XX
PS Claim 34; Page 104-106; 148pp; English.
XX
CC The ileal/renal bile acid cotransporter protein is useful in the
CC treatment of hypercholesterolaemia, diabetes, heart disease, liver
CC disease and various digestive disorders. The cDNA may by used in
CC gene therapy to restore bile acid uptake activity to patients whose
CC ileum has been surgically resected for diseases such as Crohn
CC disease, patients born with congenital defects in the bile
CC transporter, and patients suffering from adult-onset chronic
CC idiopathic bile acid diarrhoea. The DNA and protein may be used in
CC screening methods as modulators of ileal/renal bile acid cotransport
CC activity.
XX
SQ Sequence 348 AA;

Query Match 44.7%; Score 884; DB 16; Length 348;
Best Local Similarity 46.9%; Pred. No. 3.8e-88;
Matches 164; Conservative 74; Mismatches 102; Indels 10; Gaps 4;

```
Qy          7 SSSACPANSS--EEELPVGLEVHGN--LELVFTVVSTVMMGLLMFSLGCSVEIRKLWSHI 62
              :|| |  |::  | :  :  | : |  | :| : | |::: |:|||:||:||: |   |:
Db          3 NSSICNPNATICEGDSCIAPESNFNAILSVVMSTVLTILLALVMFSMGCNVELHKFLGHL 62

Qy         63 RRPWGIAVGLLCQFGLMPFTAYLLAISFSLKPVQAIAVLIMGCCPGGTISNIFTFWVDGD 122
              |||||| || |||||:|| | ::|:::| : ||||: ||| ||||||| |||  :|||||
Db         63 RRPWGIVVGFLCQFGIMPLTGFVLSVAFGILPVQAVVVLIQGCCPGGTASNILAYWVDGD 122

Qy        123 MDLSISMTTCSTVAALGMMPLCIYLYTWSWSLQQNLTIPYQNIGITLVCLTIPVAFGVYV 182
              ||||:|||||||: |||||||||:::||  |     : ||| :|| :|| | |||: |:||
Db        123 MDLSVSMTTCSTLLALGMMPLCLFIYTKMWVDSGTIVIPYDSIGTSLVALVIPVSIGMYV 182

Qy        183 NYRWPKQSKIILKIGAVVGGVLLLVVAVAGVVLAKGSWNSDITLLTISFIFPLIGHVTGF 242
              |::||:::|||||||:: | :|::::|| | :| : :|  :  |  |  |:|: |:  ||
Db        183 NHKWPQKAKIILKIGSIAGAILIVLIAVVGGILYQSAWTIEPKLWIIGTIYPIAGYGLGF 242

Qy        243 LLALFTHQSWQRCRTISLETGAQNIQMCITMLQLSFTAEHLVQMLSFPLAYGLFQLIDGF 302
               ||    | | ||||::|||| || |:| |::|||||: | |  : :||| | :||:
Db        243 FLARIAGQPWYRCRTVALETGLQNTQLCSTIVQLSFSPEDLNLVFTFPLIYSIFQIAFAA 302

Qy        303 LIVAAYQTYKRRLKNKHGKKNSGCTEVCHTRKS--TSSRETNAFLEVNEE 350
              ::: ||  ||:     ||| |:   |         :| :|||   : :|:
Db        303 ILLGAYVAYKK----CHGKNNTELQEKTDNEMEPRSSFQETNKGFQPDEK 348
```

RESULT 2
AAR77225
ID AAR77225 standard; Protein; 348 AA.
XX
AC AAR77225;
XX
DT 17-DEC-1995 (first entry)
XX
DE Human ileal/renal bile acid cotransporter.
XX
KW Ileal/renal bile acid cotransporter; therapeutic; gene therapy;
KW diagnostic.
XX
OS Homo sapiens.
XX
PN WO9517905-A1.
XX
PD 06-JUL-1995.
XX
PF 29-DEC-1994; 94WO-US14431.
XX
PR 29-DEC-1993; 93US-0176126.
XX
PA (UYWA-) UNIV WAKE FOREST.
XX
PI Dawson PA;
XX
DR WPI; 1995-246189/32.
DR N-PSDB; AAQ91109.
XX
PT Hamster and human ileal and bile acid transport DNA and protein -
PT useful in treatment of e.g. hypercholesterolaemia, diabetes and
PT various digestive diseases, and in gene therapy to restore bile acid
PT uptake activity.
XX
PS Claim 34; Page 111-114; 148pp; English.
XX
CC The ileal/renal bile acid cotransporter protein is useful in the
CC treatment of hypercholesterolaemia, diabetes, heart disease, liver
CC disease and various digestive disorders. The cDNA may by used in
CC gene therapy to restore bile acid uptake activity to patients whose
CC ileum has been surgically resected for diseases such as Crohn
CC disease, patients born with congenital defects in the bile
CC transporter, and patients suffering from adult-onset chronic
CC idiopathic bile acid diarrhoea. The DNA and protein may be used in
CC screening methods as modulators of ileal/renal bile acid cotransport
CC activity.
XX
SQ Sequence 348 AA;

Query Match 43.5%; Score 860.5; DB 16; Length 348;
Best Local Similarity 45.6%; Pred. No. 1.4e-85;
Matches 160; Conservative 68; Mismatches 104; Indels 19; Gaps 4;

```
Qy          5 CSSSSACPANSSEEELPVGLEVHGNLELVFTVVSTVMMGLLMFSLGCSVEIRKLWSHIRR 64
              || :|    |:  :          | :| : | |::: |:|||:||:|||:|   ||:|
Db         14 CSGASCVVPESNFNNI---------LSVVLSTVLTILLALVMFSMGCNVEIKKFLGHIKR 64

Qy         65 PWGIAVGLLCQFGLMPFTAYLLAISFSLKPVQAIAVLIMGCCPGGTISNIFTFWVDGDMD 124
              |||| || |||||:|| | ::|:::| : |:||: |||:|||||| |||  :|||||||
Db         65 PWGICVGFLCQFGIMPLTGFILSVAFDILPLQAVVVLIIGCCPGGTASNILAYWVDGDMD 124

Qy        125 LSISMTTCSTVAALGMMPLCIYLYTWSWSLQQNLTIPYQNIGITLVCLTIPVAFGVYVNY 184
              ||:|||||||: |||||||||: :||  |     :: ||| ||| :|| | :||: |::||:
Db        125 LSVSMTTCSTLLALGMMPLCLLIYTKMWVDSGSIVIPYDNIGTSLVALVVPVSIGMFVNH 184

Qy        185 RWPKQSKIILKIGAVVGGVLLLVVAVAGVVLAKGSWNSDITLLTISFIFPLIGHVTGFLL 244
              :||:::|||||||:: | :|::::|| | :| : :|     |  |  |||: |:  ||||
Db        185 KWPQKAKIILKIGSIAGAILIVLIAVVGGILYQSAWIIAPKLWIIGTIFPVAGYSLGFLL 244

Qy        245 ALFTHQSWQRCRTISLETGAQNIQMCITMLQLSFTAEHLVQMLSFPLAYGLFQLIDGFLI 304
              |      | ||||:: ||| || |:| |::||||| | |  : :||| | :|||    :
Db        245 ARIAGLPWYRCRTVAFETGMQNTQLCSTIVQLSFTPEELNVVFTFPLIYSIFQLAFAAIF 304

Qy        305 VAAYQTYKRRLKNKHGKKNSGCTEVCHTRKSTSSRETNAFLEVNEEGAITP 355
              :  |  ||:     |||  :   |     |   :   ::| : |  |   |
Db        305 LGFYVAYKK----CHGKNKAEIPE----SKENGTEPESSFYKAN--GGFQP 345
```

RESULT 3
AAE13283
ID AAE13283 standard; Protein; 491 AA.
XX
AC AAE13283;
XX
DT 12-FEB-2002 (first entry)
XX
DE Human transporters and ion channels (TRICH)-10.
XX
KW Human; transporter and ion channel; TRICH; akinesia; cystic fibrosis;
KW diabetes mellitus; Parkinson's disease; myasthenia gravis; dementia;
KW cardiac disorder; angina; hypertension; myocarditis; hyperglycaemia;
KW neurological disorder; Alzheimer's disease; cataract; infertility;
KW Wilson's disease; schizophrenia; Grave's disease; addison's disease;
KW Huntington's disease; multiple sclerosis; meningitis; hypotensive;
KW cardiant; nootropic; neuroprotective; neuroleptic; ophthalmological;
KW antithyroid; anticonvulsant; goitre; antiinflammatory.
XX
OS Homo sapiens.
XX

```
FH   Key             Location/Qualifiers
FT   Domain          241..261
FT                   /label= Transmembrane_domain
FT   Domain          251..439
FT                   /note= "Sodium, acid and bile transporter domain"
FT   Domain          288..307
FT                   /label= Transmembrane_domain
FT   Domain          325..343
FT                   /label= Transmembrane_domain
FT   Domain          416..435
FT                   /label= Transmembrane_domain
XX
PN   WO200177174-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-US11206.

     06-APR-2000; 2000US-195595P.
     12-APR-2000; 2000US-196872P.
PR   20-APR-2000; 2000US-199020P.
PR   28-APR-2000; 2000US-200552P.
PR   05-MAY-2000; 2000US-202348P.
PR   11-MAY-2000; 2000US-203495P.
XX
PA   (INCY-) INCYTE GENOMICS INC.
XX
PI   Reddy R, Thornton M, Borowsky ML, Tang YT, Khan FA, Tribouley CM;
PI   Gandhi AR, Yao MG, Sanjanwala MS, Baughn MR, Nguyen DB;
PI   Policky JL, Yue H, Seilhamer JJ, Walia NK, Lal P, Kearney L;
PI   Walsh RT, Lu DAM, Lu Y, Greene BD, Raumann BE, Patterson C;
XX
DR   WPI; 2002-017448/02.
DR   N-PSDB; AAD22002.
XX
PT   Polypeptides of human transporters and ion channels, useful for
PT   diagnosing, treating or preventing disorders of transport,
PT   neurological, muscle, immunological and cell proliferative disorders -
XX
PS   Claim 1; Page 130-131; 150pp; English.
XX
CC   The invention relates to human transporters and ion channels (TRICH)
CC   and the polynucleotides encoding them. The composition comprising TRICH
CC   or agonist of TRICH is useful for treating a disease or condition
CC   associated with decreased expression of functional TRICH or condition
     associated with overexpression of TRICH respectively. The composition
     comprising Ab is useful for diagnosing a condition of disease associated
     with expression of TRICH in a subject, where the disorders include a
CC   transport disorder such as akinesia, cystic fibrosis, diabetes mellitus,
CC   Parkinson's disease, myasthenia gravis, cardiac disorders associated
CC   with transport e.g. angina, hypertension, myocarditis, neurological
CC   disorders associated with transport e.g. Alzheimer's disease, Wilson's
CC   disease, schizophrenia, cataracts, infertility, hyperglycaemia, Grave's
CC   disease, goitre, addison's disease, Huntington's disease, dementia,
CC   multiple sclerosis, bacterial and viral meningitis. TRICH DNA is useful
CC   for generating a transcript image of a tissue or cell type, which
CC   represents the global pattern of gene expression by a particular tissue
CC   or cell type and for analysing the proteome of a tissue or cell type.
CC   TRICH DNA is used in gene therapy. The present amino acid sequence is
CC   human TRICH10 protein.
XX
SQ   Sequence   491 AA;

  Query Match           19.5%;  Score 386.5;  DB 23;  Length 491;
  Best Local Similarity   27.1%;  Pred. No. 2.4e-33;
  Matches   95;  Conservative   56;  Mismatches  105;  Indels   95;  Gaps    7;

Qy         44 LLMFSLGCSVEIRKLWSHIRRPWGIAVGLLCQFGLMPFTAYLLAISFSLKPVQA--IAVL 101
              :  |||:|::    :|:|||      ||    : |  |  |    |: :    :|
Db        115 ITMLGLGCTVDVNHFGAHVRRP---VAALLAALPVRPPAAAGLPAGPRLQAGRGGRRGLL 171

Qy        102 IMGCCPGGTISNIFTFWVDGDMDL---------------------------------- 125
              : |||||| :||: :  |||||:|
Db        172 LCGCCPGGNLSNLMSLLVDGDMNLRRAALLALSSDVGSAQTSTPGLAVSPFHLYSTYKKK 231

Qy        126 ------------------SISMTTCSTVAALGMMPLCIYLYTWSW---SLQQNLTIPYQ 163
                               || ||  ||: || :||||:::|:|:|    : |   :|
Db        232 VSWLFDSKLVLISAHSLFCSIIMTISSTLLALVLMPLCLWIYSWAWINTPIVQ--LLPLG 289

Qy        164 NIGITLVCLTIPVAFGVYVNYRWPKQSKIILKI----------------GAVVGGVLLLV 207
               : :||    ||:  ||:: |:: : :  |:|:                | ::|  ||
Db        290 TVTLTLCSTLIPIGLGVFIRYKYSRVADYIVKVSLWSLLVTLVVLFIMTGTMLGPELLAS 349

Qy        208 VAVAGVVLAKGSWNSDITLLTISFIFPLIGHVTGFLLALFTHQSWQRCRTISLETGAQNI 267
              :  |  |:|                  || |: :|: ||   |      ||: ||||:||:
Db        350 IPAAVYVIA----------IFMPLAGYASGYGLATLFHLPPNCKRTVCLETGSQNV 395

Qy        268 QMCITMLQLSFTAEHLVQMLSFPLAYGLFQLIDGFLIVAAYQTYKRRLKNK 318
              |:|  :|:|:|  : :  |  ||| | |||  :  : |  |: |   : :|
Db        396 QLCTAILKLAFPPQFIGSMYMFPLLYALFQSAEAGIFVLIYKMYGSEMLHK 446


RESULT 4
AAE21252
ID   AAE21252 standard; Protein; 225 AA.
XX
AC   AAE21252;
XX
DT   01-JUL-2002  (first entry)
XX
DE   Human gene 8 encoded secreted protein fragment, SEQ ID NO:117.
XX
KW   Human; secreted protein; immune disorder; antiallergic; antirheumatic;
KW   rheumatoid arthritis; breast neoplasia; breast cancer; antiarthritic;
KW   neurological disease; Alzheimer's disease; Parkinson's disease; trauma;
KW   Tourette syndrome; encephalitis; cytostatic; haemostatic; anaemia; mania;
KW   antiinflammatory; ophthalmalogical; dermatological; immunostimulatory;
KW   immunomodulatory; immunosuppressive; antibacterial; antipsoriatic;
KW   gene therapy; autoimmune disease; Huntington's disease; meningitis;
KW   demyelinating disease; peripheral neuropathy; congenital malformation;
KW   spinal cord injury; peripheral neuropathy; ischaemia; perception;
KW   multiple sclerosis; infarction; haemorrhage; schizophrenia; dementia;
KW   depression; panic disorder; learning disability; ALS; feeding disorder;
KW   hyperproliferative disorder; sleep pattern; cardiovascular disorder;
KW   reproductive disorder; digestive system disorder; behavioural disorder.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 200
FT                   /label= Unknown
FT                   /note= "Xaa equals any of the naturally occurring
FT                   L-amino acids"
FT   Misc-difference 204
FT                   /label= Unknown
FT                   /note= "Xaa equals any of the naturally occurring
FT                   L-amino acids"
FT   Misc-difference 206
FT                   /label= Unknown
FT                   /note= "Xaa equals any of the naturally occurring
FT                   L-amino acids"
FT   Misc-difference 210
FT                   /label= Unknown
FT                   /note= "Xaa equals any of the naturally occurring
FT                   L-amino acids"
FT   Misc-difference 214
FT                   /label= Unknown
FT                   /note= "Xaa equals any of the naturally occurring
FT                   L-amino acids"
FT   Misc-difference 217
FT                   /label= Unknown
FT                   /note= "Xaa equals any of the naturally occurring
FT                   L-amino acids"
FT   Misc-difference 218
FT                   /label= Unknown
FT                   /note= "Xaa equals any of the naturally occurring
```

```
FT                   L-amino acids"
FT   Misc-difference 222
FT                   /label= Unknown
FT                   /note= "Xaa equals any of the naturally occurring
FT                   L-amino acids"
XX
PN   WO200216390-A1.
XX
PD   28-FEB-2002.
XX
PF   17-JAN-2001; 2001WO-US01435.
XX
PR   18-AUG-2000; 2000US-226282P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Komatsoulis GA,  Baker KP,  Birse CE,  Soppet DR,  Olsen HS;
PI   Moore PA,  Wei P,  Ebner R,  Duan DR,  Shi Y,  Choi GH,  Fiscella M;
PI   Ni J;
XX
     WPI; 2002-304113/34.

     An isolated nucleic acid molecule (I) comprising a polynucleotide which
PT   encodes a polypeptide useful in the diagnosis and treatment of
PT   disorders e.g. immune disorders -
XX
PS   Disclosure; Page 26; 534pp; English.
XX
CC   AAD33692-AAD33736 represent cDNAs corresponding to 21 human secreted
CC   protein genes, and AAE21191-AAE21235 represent the proteins they encode.
CC   AAE21236-AAE21280 represent human secreted protein fragments. The genes
CC   and their corresponding secreted proteins are useful for preventing,
CC   treating or ameliorating medical conditions, e.g., by protein or gene
CC   therapy. Pathological conditions can be diagnosed by determining the
CC   amount of the new protein in a sample or by determining the presence of
CC   mutations in the new genes. Specific uses are described for each of the
CC   21 genes, based on the tissues in which they are most highly expressed,
CC   and include developing products for the diagnosis or treatment of
CC   immune or autoimmune diseases e.g. AIDS (acquired immune deficiency
CC   syndrome), asthma, anaemia and rheumatoid arthritis, breast neoplasia
CC   and breast cancer, neurological diseases e.g. Alzheimer's disease,
CC   Parkinson's disease, Huntington's disease, Tourette syndrome,
CC   meningitis, demyelinating disease, peripheral neuropathies, neoplasia,
CC   trauma, congenital malformations, spinal cord injuries, toxic
CC   neuropathies induced by neurotoxins, peripheral neuropathies, multiple
CC   sclerosis, ischaemia and infarction, haemorrhages, schizophrenia, mania,
CC   dementia, depression, panic disorder, learning disabilities, ALS,
CC   altered behaviours e.g. disorders in feeding, sleep patterns, balance
CC   and perception, encephalitis, disorders in cardiovascular, neural/
CC   sensory, reproductive and digestive systems, behavioural disorders and
CC   hyperproliferative disorder. The present sequence represents human
CC   secreted protein fragment referred to in the disclosure of the invention.
XX
SQ   Sequence   225 AA;

  Query Match             18.4%;  Score 363.5;  DB 23;  Length 225;
  Best Local Similarity   35.8%;  Pred. No. 2.7e-31;
  Matches   76;  Conservative   42;  Mismatches   59;  Indels   35;  Gaps    4;

Qy         86 LAISFSLKPVQAIAVLIMGCCPGGTISNIFTFWVDGDMDLSISMTTCSTVAALGMMPLCI 145
              ||::| |  | |:|||: |||||| :||: :  |||||:||| ||  ||: || :||||:
Db          1 LALAFKLDEVAAVAVLLCGCCPGGNLSNLMSLLVDGDMNLSIIMTISSTLLALVLMPLCL 60

Qy        146 YLYTWSW---SLQQNLTIPYQNIGITLVCLTIPVAFGVYVNYRWPKQSKIILKI------ 196
              ::|:|:|    : |   :|   : :||    ||:  ||:: |:: : :  |:|:
Db         61 WIYSWAWINTPIVQ--LLPLGTVTLTLCSTLIPIGLGVFIRYKYSRVADYIVKVSLWSLL 118

Qy        197 ----------GAVVGGVLLLVVAVAGVVLAKGSWNSDITLLTISFIFPPLIGHVTGFLLAL 246
                       | ::|  ||  :  |  |:|                || |: :|: ||
Db        119 VTLVVLFIMTGTMLGPELLASIPAAVYVIA-------------IFMPLAGYASGYGLAT 164

Qy        247 FTHQSWQRCRTISLETGAQNIQMCITMLQLSF 278
                 |      ||: ||||:||:|:|  :|:|:|
```

```
Db        165 LFHLPPNCKRTVCLETGSQNVQLCTAILKLAF 196


RESULT 5
ABG00575
ID   ABG00575 standard; Protein; 454 AA.
XX
AC   ABG00575;
XX
DT   13-FEB-2002  (first entry)
XX
DE   Novel human diagnostic protein #566.
XX
KW   Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW   food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS   Homo sapiens.
XX
PN   WO200175067-A2.
XX
PD   11-OCT-2001.
XX
PF   30-MAR-2001; 2001WO-US08631.
XX
PR   31-MAR-2000; 2000US-0540217.
PR   23-AUG-2000; 2000US-0649167.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Drmanac RT,  Liu C,  Tang YT;
XX
DR   WPI; 2001-639362/73.
DR   N-PSDB; AAS64762.
XX
PT   New isolated polynucleotide and encoded polypeptides, useful in
PT   diagnostics, forensics, gene mapping, identification of mutations
PT   responsible for genetic disorders or other traits and to assess
PT   biodiversity  -
XX
PS   Claim 20; SEQ ID No 30934; 103pp; English.
XX
CC   The invention relates to isolated polynucleotide (I) and
CC   polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC   polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC   and gene mapping, and in recombinant production of (II). The
CC   polynucleotides are also used in diagnostics as expressed sequence tags
CC   for identifying expressed genes. (I) is useful in gene therapy techniques
CC   to restore normal activity of (II) or to treat disease states involving
CC   (II). (II) is useful for generating antibodies against it, detecting or
CC   quantitating a polypeptide in tissue, as molecular weight markers and as
CC   a food supplement. (II) and its binding partners are useful in medical
CC   imaging of sites expressing (II). (I) and (II) are useful for treating
CC   disorders involving aberrant protein expression or biological activity.
CC   The polypeptide and polynucleotide sequences have applications in
CC   diagnostics, forensics, gene mapping, identification of mutations
CC   responsible for genetic disorders or other traits to assess biodiversity
CC   and to produce other types of data and products dependent on DNA and
CC   amino acid sequences. ABG00010-ABG30377 represent novel human
CC   diagnostic amino acid sequences of the invention.
CC   Note: The sequence data for this patent did not appear in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   454 AA;

  Query Match             17.9%;  Score 354.5;  DB 22;  Length 454;
  Best Local Similarity   50.4%;  Pred. No. 6.9e-30;
  Matches   61;  Conservative   24;  Mismatches   27;  Indels    9;  Gaps    1;

Qy          5 CSSSSACPANSSEEELPVGLEVHGNLELVFTVVSTVMMGLLMFSLGCSVEIRKLWSHIRR 64
              || :|     |:   :         | :| : | |::: |:|||:||:|||:|   ||:|
Db        259 CSGASCVVPESNFNNI---------LSVVLSTVLTILLALVMFSMGCNVEIKKFLGHIKR 309
```

```
Qy          65 PWGIAVGLLCQFGLMPFTAYLLAISFSLKPVQAIAVLIMGCCPGGTISNIFTFWVDGDMD 124
               |||| || |||||:|| | ::|:::| : |:||: |||:|||||| |||  :|||||||
Db         310 PWGICVGFLCQFGIMPLTGFILSVAFDILPLQAVVVLIIGCCPGGTASNILAYWVDGDMD 369

Qy         125 L 125
               |
Db         370 L 370
```

RESULT 6
AAE21253
ID AAE21253 standard; Protein; 207 AA.
XX
AC AAE21253;
XX
DT 01-JUL-2002 (first entry)
XX
Human gene 8 encoded secreted protein fragment, SEQ ID NO:118.
;
Human; secreted protein; immune disorder; antiallergic; antirheumatic;
KW rheumatoid arthritis; breast neoplasia; breast cancer; antiarthritic;
KW neurological disease; Alzheimer's disease; Parkinson's disease; trauma;
KW Tourette syndrome; encephalitis; cytostatic; haemostatic; anaemia; mania;
KW antiinflammatory; ophthalmalogical; dermatological; immunostimulatory;
KW immunomodulatory; immunosuppressive; antibacterial; antipsoriatic;
KW gene therapy; autoimmune disease; Huntington's disease; meningitis;
KW demyelinating disease; peripheral neuropathy; congenital malformation;
KW spinal cord injury; peripheral neuropathy; ischaemia; perception;
KW multiple sclerosis; infarction; haemorrhage; schizophrenia; dementia;
KW depression; panic disorder; learning disability; ALS; feeding disorder;
KW hyperproliferative disorder; sleep pattern; cardiovascular disorder;
KW reproductive disorder; digestive system disorder; behavioural disorder.
XX
OS Homo sapiens.
XX
PN WO200216390-A1.
XX
PD 28-FEB-2002.
XX
PF 17-JAN-2001; 2001WO-US01435.
XX
PR 18-AUG-2000; 2000US-226282P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
Rosen CA, Komatsoulis GA, Baker KP, Birse CE, Soppet DR, Olsen HS;
Moore PA, Wei P, Ebner R, Duan DR, Shi Y, Choi GH, Fiscella M;
Ni J;
XX
DR WPI; 2002-304113/34.
XX
PT An isolated nucleic acid molecule (I) comprising a polynucleotide which
PT encodes a polypeptide useful in the diagnosis and treatment of
PT disorders e.g. immune disorders -
XX
PS Disclosure; Page 26; 534pp; English.
XX
CC AAD33692-AAD33736 represent cDNAs corresponding to 21 human secreted
CC protein genes, and AAE21191-AAE21235 represent the proteins they encode.
CC AAE21236-AAE21280 represent human secreted protein fragments. The genes
CC and their corresponding secreted proteins are useful for preventing,
CC treating or ameliorating medical conditions, e.g., by protein or gene
CC therapy. Pathological conditions can be diagnosed by determining the
CC amount of the new protein in a sample or by determining the presence of
CC mutations in the new genes. Specific uses are described for each of the
CC 21 genes, based on the tissues in which they are most highly expressed,
CC and include developing products for the diagnosis or treatment of
CC immune or autoimmune diseases e.g. AIDS (acquired immune deficiency
CC syndrome), asthma, anaemia and rheumatoid arthritis, breast neoplasia
CC and breast cancer, neurological diseases e.g. Alzheimer's disease,
CC Parkinson's disease, Huntington's disease, Tourette syndrome,
CC meningitis, demyelinating disease, peripheral neuropathies, neoplasia,
CC trauma, congenital malformations, spinal cord injuries, toxic
CC neuropathies induced by neurotoxins, peripheral neuropathies, multiple
CC sclerosis, ischaemia and infarction, haemorrhages, schizophrenia, mania,
CC dementia, depression, panic disorder, learning disabilities, ALS,
CC altered behaviours e.g. disorders in feeding, sleep patterns, balance
CC and perception, encephalitis, disorders in cardiovascular, neural/
CC sensory, reproductive and digestive systems, behavioural disorders and
CC hyperproliferative disorder. The present sequence represents human
CC secreted protein fragment referred to in the disclosure of the invention.
XX
SQ Sequence 207 AA;

Query Match 16.1%; Score 318.5; DB 23; Length 207;
Best Local Similarity 33.0%; Pred. No. 2.1e-26;
Matches 70; Conservative 40; Mismatches 67; Indels 35; Gaps 4;

```
Qy         119 VDGDMDLSISMTTCSTVAALGMMPLCIYLYTWSW---SLQQNLTIPYQNIGITLVCLTIP 175
               |||||:||| ||  ||: || :||||:::|:|:|    : |  :|  : :||   ||
Db           5 VDGDMNLSIIMTISSTLLALVLMPLCLWIYSWAWINTPIVQ--LLPLGTVTLTLCSTLIP 62

Qy         176 VAFGVYVNYRWPKQSKIILKI----------------GAVVGGVLLLVVAVAGVVLAKGS 219
               :  ||:: |:: : :  |:|:                | ::|  ||  :. |  |:|
Db          63 IGLGVFIRYKYSRVADYIVKVSLWSLLVTLVVLFIMTGTMLGPELLASIPAAVYVIA--- 119

Qy         220 WNSDITLLTISFIFPLIGHVTGFLLALFTHQSWQRCRTISLETGAQNIQMCITMLQLSFT 279
                           || |: :|: ||   |      ||: ||||:|||:|:|  :|:|:|
Db         120 ----------IFMPLAGYASGYGLATLFHLPPNCKRTVCLETGSQNVQLCTAILKLAFP 168

Qy         280 AEHLVQMLSFPLAYGLFQLIDGFLIVAAYQTY 311
                : :  |  ||| | |||  :  : |  |: |
Db         169 PQFIGSMYMFPLLYALFQSAEAGIFVLIYKMY 200
```

RESULT 7
ABB91897
ID ABB91897 standard; Protein; 338 AA.
XX
AC ABB91897;
XX
DT 31-MAY-2002 (first entry)
XX
DE Herbicidally active polypeptide SEQ ID NO 1108.
XX
KW Herbicidal; plant; agriculture; herbicide.
XX
OS Arabidopsis thaliana.
XX
PN WO200210210-A2.
XX
PD 07-FEB-2002.
XX
PF 28-AUG-2001; 2001WO-EP09892.
XX
PR 28-AUG-2001; 2001WO-EP09892.
XX
PA (FARB) BAYER AG.
XX
PI Tietjen K, Weidler M;
XX
DR WPI; 2002-269010/31.
XX
PT Identifying plant target proteins for herbicidally active compounds,
PT comprising aligning and comparing nucleic acid or amino acid sequences
PT from plant with nucleic acid or amino acid sequences from non-plant
PT organisms -
XX
PS Claim 5; SEQ ID NO 1108; 261pp + Sequence Listing; English.
XX
CC The invention relates to identifying target proteins
CC (ABB90790-ABB94016) for herbicidally active compounds, comprising
CC aligning and comparing nucleic acid or amino acid sequences from plant
CC with nucleic acid or amino acid sequences from non-plant organisms using
CC suitable search parameters, where plant sequences having an E-value
CC greater by a factor of 3 than the E-value of most similar non-plant

```
CC   sequences are selected. The polypeptides or nucleic acids encoding them
CC   are useful for identifying modulators. The identified modulators are
CC   useful as herbicides.
XX
SQ   Sequence   338 AA;

  Query Match             14.4%;  Score 284;  DB 23;  Length 338;
  Best Local Similarity   25.8%;  Pred. No. 2.5e-22;
  Matches   80;  Conservative   54;  Mismatches  120;  Indels   56;  Gaps    8;

Qy          9 SACPANSSEEELPVGLEVHGNL--------------ELVFTV-----------VSTVMM 42
              |  |  |:|          | |:|              ||: |:           :.|: :
Db         15 SQCRINTSRVVCKAAAGVSGDLPESTPKELSQYEKIIELLTTLFPLWVTWLETDLFTLGL 74

Qy         43 GLLMFSLGCSVEIRKLWSHIRRPWGIAVGLLCQFGLMPFTAYLLAISFSLKPVQAIAVLI 102
              | || |:| ::         :| || : || | |: : |   :|:|::  |     |  :::
Db         75 GFLMLSMGLTLTFEDFRRCLRNPWTVGVGFLAQYMIKPILGFLIAMTLKLSAPLATGLIL 134

Qy        103 MGCCPGGTISNIFTPWVDGDMDLSISMTTCSTVAALGMMPLCIYLYTWSWSLQQNLTIPY 162
              : |||||  ||: |:   |:: ||: |||||: |: | ||          |     :|
Db        135 VSCCPGGQASNVATYISKGNVALSVLMTTCSTIGAIIMTPLLT-------KLLAGQLVPV 187

          163 QNIGI---TLVCLTIPVAFGVYVNYRWPKQSKIILKIGAVVGGVLLLVVA------VAGV 213
                |:   |   : :|   ||  |  :|| :  |: :  ::| :|  ::       || |
Db        188 DAAGLALSTFQVVLVPTIIGVLANEFFPKFTSKIITVTPLIGVILTTLLCASPIGQVADV 247

Qy        214 VLAKGSWNSDITLLTISFIFPL-IGHVTGFLLALFTHQ---SWQRCRTISLETGAQNIQM 269
              :  :|:             | |: : |   | :  :  :         ||||:| | |:  :
Db        248 LKTQGA----------QLILPVALLHAAAFAIGYWISKFSFGESTSRTISIECGMQSSAL 297

Qy        270 CITMLQLSFT 279
                : |  ||
Db        298 GFLLAQKHFT 307


RESULT 8
AAG22453
ID   AAG22453 standard; Protein; 356 AA.
XX
AC   AAG22453;
XX
DT   17-OCT-2000  (first entry)
XX
DE   Arabidopsis thaliana protein fragment SEQ ID NO: 25387.
XX
KW   Protein identification; signal transduction pathway; metabolic pathway;
KW   hybridisation assay; genetic mapping; gene expression control; promoter;
KW   termination sequence.
XX
OS   Arabidopsis thaliana.
XX
PN   EP1033405-A2.
XX
PD   06-SEP-2000.
XX
PF   25-FEB-2000; 2000EP-0301439.
XX
PR   25-FEB-1999;   99US-0121825.
PR   05-MAR-1999;   99US-0123180.
PR   09-MAR-1999;   99US-0123548.
PR   23-MAR-1999;   99US-0125788.
PR   25-MAR-1999;   99US-0126264.
PR   29-MAR-1999;   99US-0126785.
PR   01-APR-1999;   99US-0127462.
PR   06-APR-1999;   99US-0128234.
PR   08-APR-1999;   99US-0128714.
PR   16-APR-1999;   99US-0129845.
PR   19-APR-1999;   99US-0130077.
PR   21-APR-1999;   99US-0130449.
PR   23-APR-1999;   99US-0130510.
PR   23-APR-1999;   99US-0130891.
PR   28-APR-1999;   99US-0131449.
PR   30-APR-1999;   99US-0132048.
PR   30-APR-1999;   99US-0132407.
PR   04-MAY-1999;   99US-0132484.
PR   05-MAY-1999;   99US-0132485.
PR   06-MAY-1999;   99US-0132486.
PR   06-MAY-1999;   99US-0132487.
PR   07-MAY-1999;   99US-0132863.
PR   11-MAY-1999;   99US-0134256.
PR   14-MAY-1999;   99US-0134218.
PR   14-MAY-1999;   99US-0134219.
PR   14-MAY-1999;   99US-0134221.
PR   14-MAY-1999;   99US-0134370.
PR   18-MAY-1999;   99US-0134768.
PR   19-MAY-1999;   99US-0134941.
PR   20-MAY-1999;   99US-0135124.
PR   21-MAY-1999;   99US-0135353.
PR   24-MAY-1999;   99US-0135629.
PR   25-MAY-1999;   99US-0136021.
PR   27-MAY-1999;   99US-0136392.
PR   28-MAY-1999;   99US-0136782.
PR   01-JUN-1999;   99US-0137222.
PR   03-JUN-1999;   99US-0137528.
PR   04-JUN-1999;   99US-0137502.
PR   07-JUN-1999;   99US-0137724.
PR   08-JUN-1999;   99US-0138094.
PR   10-JUN-1999;   99US-0138540.
PR   10-JUN-1999;   99US-0138847.
PR   14-JUN-1999;   99US-0139119.
PR   16-JUN-1999;   99US-0139452.
PR   16-JUN-1999;   99US-0139453.
PR   17-JUN-1999;   99US-0139492.
PR   18-JUN-1999;   99US-0139454.
PR   18-JUN-1999;   99US-0139455.
PR   18-JUN-1999;   99US-0139456.
PR   18-JUN-1999;   99US-0139457.
PR   18-JUN-1999;   99US-0139458.
PR   18-JUN-1999;   99US-0139459.
PR   18-JUN-1999;   99US-0139460.
PR   18-JUN-1999;   99US-0139461.
PR   18-JUN-1999;   99US-0139462.
PR   18-JUN-1999;   99US-0139463.
PR   18-JUN-1999;   99US-0139750.
PR   18-JUN-1999;   99US-0139763.
PR   21-JUN-1999;   99US-0139817.
PR   22-JUN-1999;   99US-0139899.
PR   23-JUN-1999;   99US-0140353.
PR   23-JUN-1999;   99US-0140354.
PR   24-JUN-1999;   99US-0140695.
PR   28-JUN-1999;   99US-0140823.
PR   29-JUN-1999;   99US-0140991.
PR   30-JUN-1999;   99US-0141287.
PR   01-JUL-1999;   99US-0141842.
PR   01-JUL-1999;   99US-0142154.
PR   02-JUL-1999;   99US-0142055.
PR   06-JUL-1999;   99US-0142390.
PR   08-JUL-1999;   99US-0142803.
PR   09-JUL-1999;   99US-0142920.
PR   12-JUL-1999;   99US-0142977.
PR   13-JUL-1999;   99US-0143542.
PR   14-JUL-1999;   99US-0143624.
PR   15-JUL-1999;   99US-0144005.
PR   16-JUL-1999;   99US-0144085.
PR   16-JUL-1999;   99US-0144086.
PR   19-JUL-1999;   99US-0144325.
PR   19-JUL-1999;   99US-0144331.
PR   19-JUL-1999;   99US-0144332.
PR   19-JUL-1999;   99US-0144333.
PR   19-JUL-1999;   99US-0144334.
PR   19-JUL-1999;   99US-0144335.
PR   20-JUL-1999;   99US-0144352.
PR   20-JUL-1999;   99US-0144632.
PR   20-JUL-1999;   99US-0144884.
PR   21-JUL-1999;   99US-0144814.
PR   21-JUL-1999;   99US-0145086.
```

PR 21-JUL-1999; 99US-0145088.
PR 22-JUL-1999; 99US-0145085.
PR 22-JUL-1999; 99US-0145087.
PR 22-JUL-1999; 99US-0145089.
PR 22-JUL-1999; 99US-0145192.
PR 23-JUL-1999; 99US-0145145.
PR 23-JUL-1999; 99US-0145218.
PR 23-JUL-1999; 99US-0145224.
PR 26-JUL-1999; 99US-0145276.
PR 27-JUL-1999; 99US-0145913.
PR 27-JUL-1999; 99US-0145918.
PR 27-JUL-1999; 99US-0145919.
PR 28-JUL-1999; 99US-0145951.
PR 02-AUG-1999; 99US-0146386.
PR 02-AUG-1999; 99US-0146388.
PR 02-AUG-1999; 99US-0146389.
PR 03-AUG-1999; 99US-0147038.
04-AUG-1999; 99US-0147204.
04-AUG-1999; 99US-0147302.
05-AUG-1999; 99US-0147192.
PR 05-AUG-1999; 99US-0147260.
PR 06-AUG-1999; 99US-0147303.
PR 06-AUG-1999; 99US-0147416.
PR 09-AUG-1999; 99US-0147493.
PR 09-AUG-1999; 99US-0147935.
PR 10-AUG-1999; 99US-0148171.
PR 11-AUG-1999; 99US-0148319.
PR 12-AUG-1999; 99US-0148341.
PR 13-AUG-1999; 99US-0148565.
PR 13-AUG-1999; 99US-0148684.
PR 16-AUG-1999; 99US-0149368.
PR 17-AUG-1999; 99US-0149175.
PR 18-AUG-1999; 99US-0149426.
PR 20-AUG-1999; 99US-0149722.
PR 20-AUG-1999; 99US-0149723.
PR 20-AUG-1999; 99US-0149929.
PR 23-AUG-1999; 99US-0149902.
PR 23-AUG-1999; 99US-0149930.
PR 25-AUG-1999; 99US-0150566.
PR 26-AUG-1999; 99US-0150884.
PR 27-AUG-1999; 99US-0151065.
PR 27-AUG-1999; 99US-0151066.
PR 27-AUG-1999; 99US-0151080.
PR 30-AUG-1999; 99US-0151303.
PR 31-AUG-1999; 99US-0151438.
PR 01-SEP-1999; 99US-0151930.
PR 07-SEP-1999; 99US-0152363.
PR 10-SEP-1999; 99US-0153070.
PR 13-SEP-1999; 99US-0153758.
PR 15-SEP-1999; 99US-0154018.
PR 16-SEP-1999; 99US-0154039.
PR 20-SEP-1999; 99US-0154779.
PR 22-SEP-1999; 99US-0155139.
PR 23-SEP-1999; 99US-0155486.
PR 24-SEP-1999; 99US-0155659.
PR 28-SEP-1999; 99US-0156458.
PR 29-SEP-1999; 99US-0156596.
PR 04-OCT-1999; 99US-0157117.
PR 05-OCT-1999; 99US-0157753.
PR 06-OCT-1999; 99US-0157865.
PR 07-OCT-1999; 99US-0158029.
PR 08-OCT-1999; 99US-0158232.
PR 12-OCT-1999; 99US-0158369.
PR 13-OCT-1999; 99US-0159293.
PR 13-OCT-1999; 99US-0159294.
PR 13-OCT-1999; 99US-0159295.
PR 14-OCT-1999; 99US-0159329.
PR 14-OCT-1999; 99US-0159330.
PR 14-OCT-1999; 99US-0159331.
PR 14-OCT-1999; 99US-0159637.
PR 14-OCT-1999; 99US-0159638.
PR 18-OCT-1999; 99US-0159584.
PR 21-OCT-1999; 99US-0160741.
PR 21-OCT-1999; 99US-0160767.
PR 21-OCT-1999; 99US-0160768.
PR 21-OCT-1999; 99US-0160770.
PR 21-OCT-1999; 99US-0160814.
PR 21-OCT-1999; 99US-0160815.
PR 22-OCT-1999; 99US-0160980.
PR 22-OCT-1999; 99US-0160981.
PR 22-OCT-1999; 99US-0160989.
PR 25-OCT-1999; 99US-0161404.
PR 25-OCT-1999; 99US-0161405.
PR 25-OCT-1999; 99US-0161406.
PR 26-OCT-1999; 99US-0161359.
PR 26-OCT-1999; 99US-0161360.
PR 26-OCT-1999; 99US-0161361.
PR 28-OCT-1999; 99US-0161920.
PR 28-OCT-1999; 99US-0161992.
PR 28-OCT-1999; 99US-0161993.
PR 29-OCT-1999; 99US-0162142.

Query Match 14.1%; Score 280; DB 21; Length 356;
Best Local Similarity 27.5%; Pred. No. 7.4e-22;
Matches 71; Conservative 50; Mismatches 107; Indels 30; Gaps 6;

```
Qy         35 TVVSTVMMGLLMFSLGCSVEIRKLWSHIRRPWGIAVGLLCQFGLMPFTAYLLAISFSLKP 94
              | : |: :| || |:| ::        :| || : || | |: : |   :|:|::  |
Db         75 TDLFTLGLGFLMLSMGLTLTFEDFRRCLRNPWTVGVGFLAQYMIKPILGFLIAMTLKLSA 134

Qy         95 VQAIAVLIMGCCPGGTISNIFTFWVDGDMDLSISMTTCSTVAALGMMPLCIYLYTWSWSL 154
                |  :::: ||||| ||: |:   |:: ||: |||||: |: | ||          |
Db        135 PLATGLILVSCCPGGQASNVATYISKGNVALSVLMTTCSTIGAIIMTPLLT-------KL 187

Qy        155 QQNLTIPYQNIGI---TLVCLTIPVAFGVYVNYRWPKQSKIILKIGAVVGGVLLLVVA-- 209
                  :|    |:   |   : :|   ||  |  :|| :  |: :  ::| :|  ::
Db        188 LAGQLVPVDAAGLALSTFQVVLVPTIIGVLANEFFPKFTSKIITVTPLIGVILTTLLCAS 247

Qy        210 ----VAGVVLAKGSWNSDITLLTISFIFPL-IGHVTGFLLALFTHQ---SWQRCRTISLE 261
                  || |:  :|:           | |: : |   | :  :  :       ||||:|
Db        248 PIGQVADVLKTQGA----------QLILPVALLHAAAFAIGYWISKFSFGESTSRTISIE 297

Qy        262 TGAQNIQMCITMLQLSFT 279
               | |:  :   : |  ||
Db        298 CGMQSSALGFLLAQKHFT 315
```

RESULT 9
AAG48158
ID AAG48158 standard; Protein; 423 AA.
XX
AC AAG48158;
XX
DT 18-OCT-2000 (first entry)
XX
DE Arabidopsis thaliana protein fragment SEQ ID NO: 60787.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence.
XX
OS Arabidopsis thaliana.
XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-0301439.
XX
PR 25-FEB-1999; 99US-0121825.
PR 05-MAR-1999; 99US-0123180.
PR 09-MAR-1999; 99US-0123548.
PR 23-MAR-1999; 99US-0125788.
PR 25-MAR-1999; 99US-0126264.
PR 29-MAR-1999; 99US-0126785.
PR 01-APR-1999; 99US-0127462.

PR 06-APR-1999; 99US-0128234.
PR 08-APR-1999; 99US-0128714.
PR 16-APR-1999; 99US-0129845.
PR 19-APR-1999; 99US-0130077.
PR 21-APR-1999; 99US-0130449.
PR 23-APR-1999; 99US-0130510.
PR 23-APR-1999; 99US-0130891.
PR 28-APR-1999; 99US-0131449.
PR 30-APR-1999; 99US-0132048.
PR 30-APR-1999; 99US-0132407.
PR 04-MAY-1999; 99US-0132484.
PR 05-MAY-1999; 99US-0132485.
PR 06-MAY-1999; 99US-0132486.
PR 06-MAY-1999; 99US-0132487.
PR 07-MAY-1999; 99US-0132863.
PR 11-MAY-1999; 99US-0134256.
PR 14-MAY-1999; 99US-0134218.
PR 14-MAY-1999; 99US-0134219.
PR 14-MAY-1999; 99US-0134221.
PR 14-MAY-1999; 99US-0134370.
18-MAY-1999; 99US-0134768.
19-MAY-1999; 99US-0134941.
20-MAY-1999; 99US-0135124.
PR 21-MAY-1999; 99US-0135353.
PR 24-MAY-1999; 99US-0135629.
PR 25-MAY-1999; 99US-0136021.
PR 27-MAY-1999; 99US-0136392.
PR 28-MAY-1999; 99US-0136782.
PR 01-JUN-1999; 99US-0137222.
PR 03-JUN-1999; 99US-0137528.
PR 04-JUN-1999; 99US-0137502.
PR 07-JUN-1999; 99US-0137724.
PR 08-JUN-1999; 99US-0138094.
PR 10-JUN-1999; 99US-0138540.
PR 10-JUN-1999; 99US-0138847.
PR 14-JUN-1999; 99US-0139119.
PR 16-JUN-1999; 99US-0139452.
PR 16-JUN-1999; 99US-0139453.
PR 17-JUN-1999; 99US-0139492.
PR 18-JUN-1999; 99US-0139454.
PR 18-JUN-1999; 99US-0139455.
PR 18-JUN-1999; 99US-0139456.
PR 18-JUN-1999; 99US-0139457.
PR 18-JUN-1999; 99US-0139458.
PR 18-JUN-1999; 99US-0139459.
PR 18-JUN-1999; 99US-0139460.
PR 18-JUN-1999; 99US-0139461.
PR 18-JUN-1999; 99US-0139462.
PR 18-JUN-1999; 99US-0139463.
PR 18-JUN-1999; 99US-0139750.
18-JUN-1999; 99US-0139763.
PR 21-JUN-1999; 99US-0139817.
PR 22-JUN-1999; 99US-0139899.
PR 23-JUN-1999; 99US-0140353.
PR 23-JUN-1999; 99US-0140354.
PR 24-JUN-1999; 99US-0140695.
PR 28-JUN-1999; 99US-0140823.
PR 29-JUN-1999; 99US-0140991.
PR 30-JUN-1999; 99US-0141287.
PR 01-JUL-1999; 99US-0141842.
PR 01-JUL-1999; 99US-0142154.
PR 02-JUL-1999; 99US-0142055.
PR 06-JUL-1999; 99US-0142390.
PR 08-JUL-1999; 99US-0142803.
PR 09-JUL-1999; 99US-0142920.
PR 12-JUL-1999; 99US-0142977.
PR 13-JUL-1999; 99US-0143542.
PR 14-JUL-1999; 99US-0143624.
PR 15-JUL-1999; 99US-0144005.
PR 16-JUL-1999; 99US-0144085.
PR 16-JUL-1999; 99US-0144086.
PR 19-JUL-1999; 99US-0144325.
PR 19-JUL-1999; 99US-0144331.
PR 19-JUL-1999; 99US-0144332.
PR 19-JUL-1999; 99US-0144333.
PR 19-JUL-1999; 99US-0144334.
PR 19-JUL-1999; 99US-0144335.
PR 20-JUL-1999; 99US-0144352.
PR 20-JUL-1999; 99US-0144632.
PR 20-JUL-1999; 99US-0144884.
PR 21-JUL-1999; 99US-0144814.
PR 21-JUL-1999; 99US-0145086.
PR 21-JUL-1999; 99US-0145088.
PR 22-JUL-1999; 99US-0145085.
PR 22-JUL-1999; 99US-0145087.
PR 22-JUL-1999; 99US-0145089.
PR 22-JUL-1999; 99US-0145192.
PR 23-JUL-1999; 99US-0145145.
PR 23-JUL-1999; 99US-0145218.
PR 23-JUL-1999; 99US-0145224.
PR 26-JUL-1999; 99US-0145276.
PR 27-JUL-1999; 99US-0145913.
PR 27-JUL-1999; 99US-0145918.
PR 27-JUL-1999; 99US-0145919.
PR 28-JUL-1999; 99US-0145951.
PR 02-AUG-1999; 99US-0146386.
PR 02-AUG-1999; 99US-0146388.
PR 02-AUG-1999; 99US-0146389.
PR 03-AUG-1999; 99US-0147038.
PR 04-AUG-1999; 99US-0147204.
PR 04-AUG-1999; 99US-0147302.
PR 05-AUG-1999; 99US-0147192.
PR 05-AUG-1999; 99US-0147260.
PR 06-AUG-1999; 99US-0147303.
PR 06-AUG-1999; 99US-0147416.
PR 09-AUG-1999; 99US-0147493.
PR 09-AUG-1999; 99US-0147935.
PR 10-AUG-1999; 99US-0148171.
PR 11-AUG-1999; 99US-0148319.
PR 12-AUG-1999; 99US-0148341.
PR 13-AUG-1999; 99US-0148565.
PR 13-AUG-1999; 99US-0148684.
PR 16-AUG-1999; 99US-0149368.
PR 17-AUG-1999; 99US-0149175.
PR 18-AUG-1999; 99US-0149426.
PR 20-AUG-1999; 99US-0149722.
PR 20-AUG-1999; 99US-0149723.
PR 20-AUG-1999; 99US-0149929.
PR 23-AUG-1999; 99US-0149902.
PR 23-AUG-1999; 99US-0149930.
PR 25-AUG-1999; 99US-0150566.
PR 26-AUG-1999; 99US-0150884.
PR 27-AUG-1999; 99US-0151065.
PR 27-AUG-1999; 99US-0151066.
PR 27-AUG-1999; 99US-0151080.
PR 30-AUG-1999; 99US-0151303.
PR 31-AUG-1999; 99US-0151438.
PR 01-SEP-1999; 99US-0151930.
PR 07-SEP-1999; 99US-0152363.
PR 10-SEP-1999; 99US-0153070.
PR 13-SEP-1999; 99US-0153758.
PR 15-SEP-1999; 99US-0154018.
PR 16-SEP-1999; 99US-0154039.
PR 20-SEP-1999; 99US-0154779.
PR 22-SEP-1999; 99US-0155139.
PR 23-SEP-1999; 99US-0155486.
PR 24-SEP-1999; 99US-0155659.
PR 28-SEP-1999; 99US-0156458.
PR 29-SEP-1999; 99US-0156596.
PR 04-OCT-1999; 99US-0157117.
PR 05-OCT-1999; 99US-0157753.
PR 06-OCT-1999; 99US-0157865.
PR 07-OCT-1999; 99US-0158029.
PR 08-OCT-1999; 99US-0158232.
PR 12-OCT-1999; 99US-0158369.
PR 13-OCT-1999; 99US-0159293.

```
PR   13-OCT-1999;   99US-0159294.
PR   13-OCT-1999;   99US-0159295.
PR   14-OCT-1999;   99US-0159329.
PR   14-OCT-1999;   99US-0159330.
PR   14-OCT-1999;   99US-0159331.
PR   14-OCT-1999;   99US-0159637.
PR   14-OCT-1999;   99US-0159638.
PR   18-OCT-1999;   99US-0159584.
PR   21-OCT-1999;   99US-0160741.
PR   21-OCT-1999;   99US-0160767.
PR   21-OCT-1999;   99US-0160768.
PR   21-OCT-1999;   99US-0160770.
PR   21-OCT-1999;   99US-0160814.
PR   21-OCT-1999;   99US-0160815.
PR   22-OCT-1999;   99US-0160980.
PR   22-OCT-1999;   99US-0160981.
PR   22-OCT-1999;   99US-0160989.
     25-OCT-1999;   99US-0161404.
     25-OCT-1999;   99US-0161405.
     25-OCT-1999;   99US-0161406.
PR   26-OCT-1999;   99US-0161359.
PR   26-OCT-1999;   99US-0161360.
PR   26-OCT-1999;   99US-0161361.
PR   28-OCT-1999;   99US-0161920.
PR   28-OCT-1999;   99US-0161992.
PR   28-OCT-1999;   99US-0161993.
PR   29-OCT-1999;   99US-0162142.

  Query Match             13.8%;  Score 273;  DB 21;  Length 423;
  Best Local Similarity   26.1%;  Pred. No. 5.5e-21;
  Matches   71;  Conservative   50;  Mismatches  107;  Indels   44;  Gaps    6;

Qy         35 TVVSTVMMGLLMFSLGCSVEIRKLWSHIRRPWGIAVGLLCQFGLMPFTAYLLAISFSLKP 94
              | : |: :| || |:| ::         :| || : || | |: : |   :|:|::  |
Db        128 TDLFTLGLGFLMLSMGLTLTFEDFRRCLRNPWTVGVGFLAQYMIKPILGFLIAMTLKLSA 187

Qy         95 VQAIAVLIMGCCPGGTISNIFTFWVDGDMDLSISMTTCSTVAALGMMPLCIYLYTWSWSL 154
                |  :::: ||||| ||: |:   |:: ||: |||||: |: | ||          |
Db        188 PLATGLILVSCCPGGQASNVATYISKGNVALSVLMTTCSTIGAIIMTPLLT-------KL 240

Qy        155 QQNLTIPYQNIGI---TLVCLTIPVAFGVYVNYRWPKQSKIILKIGAVVGGVLLLVVA-- 209
                :|    |:   |   : :|   || |  :|| :  |: :  ::| :|  ::
Db        241 LAGQLVPVDAAGLALSTFQVVLVPTIIGVLANEFFPKFTSKIITVTPLIGVILTTLLCAS 300

Qy        210 ------------------VAGVVLAKGSWNSDITLLTISFIFPL-IGHVTGFLLALFTHQ 250
                             || |:  :|:           | |: : |   | :  :  :
Db        301 PTGIGIDYYLISSEKIGQVADVLKTQGA----------QLILPVALLHAAAFAIGYWISK 350

Qy        251 ---SWQRCRTISLETGAQNIQMCITMLQLSFT 279
                   ||||:| | |:  :   : |  ||
Db        351 FSFGESTSRTISIECGMQSSALGFLLAQKHFT 382


RESULT 10
AAG91138
ID   AAG91138 standard; Protein; 335 AA.
XX
AC   AAG91138;
XX
DT   26-SEP-2001  (first entry)
XX
DE   C glutamicum protein fragment SEQ ID NO: 4892.
XX
KW   Coryneform bacterium; amino acid synthesis; vitamin; saccharide;
KW   organic acid synthesis.
XX
OS   Corynebacterium glutamicum.
XX
PN   EP1108790-A2.
XX
PD   20-JUN-2001.
XX
PF   18-DEC-2000; 2000EP-0127688.
XX
PR   16-DEC-1999;   99JP-0377484.
PR   07-APR-2000; 2000JP-0159162.
PR   03-AUG-2000; 2000JP-0280988.
XX
PA   (KYOW ) KYOWA HAKKO KOGYO KK.
XX
PI   Nakagawa S,  Mizoguchi H,  Ando S,  Hayashi M,  Ochiai K,  Yokoi H;
PI   Tateishi N,  Senoh A,  Ikeda M,  Ozaki A;
XX
DR   WPI; 2001-376931/40.
DR   N-PSDB; AAH66357.
XX
PT   Novel polynucleotides derived from Coryneform bacteria, for identifying
PT   mutation point of a gene, measuring expression of a gene, analysing
PT   expression profile or pattern of a gene and identifying homologous gene
PT   -
XX
PS   Claim 17; SEQ ID NO: 4892; 246pp + Sequence Listing; English.
XX
CC   The present invention provides a number of nucleotide and protein
CC   sequences from the Coryneform bacterium Corynebacterium glutamicum. These
CC   are useful for identifying the mutation point of a gene derived from a
CC   mutant of coryneform bacterium, measuring expression amount and
CC   analysing the expression profile or expression pattern of a gene derived
CC   from Coryneform bacterium, and identifying a homologue of a gene derived
CC   from coryneform bacterium. Coryneform bacteria are useful for producing
CC   amino acids, nucleic acids, vitamins, saccharides and organic acids,
CC   particularly L-lysine. The present sequence is a protein described
CC   in the exemplification of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from the
CC   European Patent Office.
XX
SQ   Sequence   335 AA;

  Query Match             13.6%;  Score 268.5;  DB 22;  Length 335;
  Best Local Similarity   25.7%;  Pred. No. 1.2e-20;
  Matches   76;  Conservative   72;  Mismatches  127;  Indels   21;  Gaps    7;

Qy         31 ELVFTVVSTV--MMGLLMFSLGCSVEIRKLWSHIRRPWGIAVGLLCQFGLMPFTAYLLAI 88
              ::|  : | |  ::|::|||:| :::         :||  : :|:: || :||  | |:
Db         40 DVVLNISSWVNPLLGIIMFSMGLTLKPVDFALVAKRPLPVLIGVIAQFVIMPLIALLVVW 99

Qy         89 SFSLKPVQAIAVLIMGCCPGGTISNIFTFWVDGDMDLSISMTTCSTVAALGMMPLCIYLY 148
                 |    |  |:::|| |||| ||: ::   ||: ||::||: ||: |    ||
Db        100 VLQLPAEIAAGVILVGCAPGGTSSNVVSYLSRGDVALSVTMTSISTLLAPIFTPLLTL-- 157

Qy        149 TWSWSLQQNLTIPYQNIGITLV-CLTIPVAFGVYVNYRWPKQSKIILKIGAVVGGVLLLV 207
                 |    | : :   :: :::|  : |||  |: |   :|    :| |:  ::  : ::
Db        158 ---WLAGQYMPLNAADMAVSIVQVVLIPVVGGLVVRLIFP---TLIGKVLPLLPWISVIA 211

Qy        208 VAVAGVVLAKGS----WNSDITLLTISFIFPLIGHVTGFLLALFTHQSWQRCRTISLETG 263
              :::   ::  ||     : : :|    |  :|:  |:| | || |    || ::| |
Db        212 ISLIVAIVVAGSRDKILEAGLLVLAAVIIHNTLGYSLGYLAAKFTGQPAAARRTTAIEVG 271

Qy        264 AQNIQMCITMLQLSFTAEHLVQMLSFPLA-YGLFQLIDGFLIVAAYQTYKRRLKNK 318
               ||     : |     ::::  | : | | : ::  :  | |: |  :   :|   |
Db        272 MQN-----SGLAAGLASQYMSPMSALPGAIFSVWHNLSGALLAALCRASDKRAAEK 322


RESULT 11
ABB70896
ID   ABB70896 standard; Protein; 455 AA.
XX
AC   ABB70896;
XX
DT   26-MAR-2002  (first entry)
XX
DE   Drosophila melanogaster polypeptide SEQ ID NO 39480.
XX
KW   Drosophila; developmental biology; cell signalling; insecticide;
KW   pharmaceutical.
```

```
XX
OS   Drosophila melanogaster.
XX
PN   WO200171042-A2.
XX
PD   27-SEP-2001.
XX
PF   23-MAR-2001; 2001WO-US09231.
XX
PR   23-MAR-2000; 2000US-191637P.
PR   11-JUL-2000; 2000US-0614150.
XX
PA   (PEKE ) PE CORP NY.
XX
PI   Venter JC,  Adams M,  Li PWD,  Myers EW;
XX
DR   WPI; 2001-656860/75.
DR   N-PSDB; ABL14999.
XX
PT   New isolated nucleic acid detection reagent for detecting 1000 or more
     genes from Drosophila and for elucidating cell signalling and cell-cell
     interactions -

PS   Disclosure; SEQ ID NO 39480; 21pp + Sequence Listing; English.
XX
CC   The invention relates to an isolated nucleic acid detection reagent
CC   capable of detecting 1000 or more genes from Drosophila. The invention is
CC   useful in developmental biology and in elucidating cell signalling and
CC   cell-cell interactions in higher eukaryotes for the development of
CC   insecticides, therapeutics and pharmaceutical drugs. The invention
CC   discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
CC   sequences (ABL01840-ABL16175) and the encoded proteins
CC   (ABB57737-ABB72072).
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   455 AA;

  Query Match             13.4%;  Score 266;  DB 22;  Length 455;
  Best Local Similarity   26.6%;  Pred. No. 3.6e-20;
  Matches   75;  Conservative   57;  Mismatches  126;  Indels   24;  Gaps    7;

Qy           7 SSSACPAN-SSEEELPVGLEVHGN-LELVPTVVSTVMMGLLMFSLGCSVEIRKLWSHIRR 64
               ::|  | | |::  | | ::    :: :|    ::| ||  | | :: :  |   | |
Db         124 NTSELPTNWSNDSTLDVKIKRPKRVVDDIFLGTIILLMSLLYISFGAALNLDVLRGLITR 183

Qy          65 PWGIAVGLLCQFGLMPFTAYLLAI-SFSLKPVQAIAVLIMGCCPGGTISNIFTFWVDGDM 123
               | |  :| : |   ||  :| | :  |   |   : :   |  | |  || ::  : |::
Db         184 PTGPCIGFVMQVVGMPLLSYALGVFIFPQAPAMQLGLFFTGISPSGGASNTWSAVLGGNI 243

Qy         124 DLSISMTTCSTVAALGMMPLCIYLYTWSWSLQQ------NLTIPYQNIGITLVCLTIPVA 177
                ||: ||| | |||   :||      |: :| |       : :|| |      | :|:
Db         244 HLSVLMTTVSNVAAFATIPL------WTITLGQLIFERAGIKVPYGKIASYSSSLVLPLL 297

Qy         178 FGVYVNYRWPKQSKIILKIGAVVGGVLLLVVAVAGVV-----LAKGSWNSDITLLTISFI 232
               |: |  | |: :::::::   |   ::| : |  ::          ||     ::
Db         298 LGLLVQKRMPQVARVLVRLLKPVSAFIILFIIVFAIINNFYLFYLFSWQ----IVVAGMA 353

Qy         233 FPLIGHVTGFLLALFTHQSWQRCRTISLETGAQNIQMCITML 274
                | :|::  || |   ||:     ||::||| ||  : | :|
Db         354 LPGLGYIFAFLAAKLLHQNAADALTIAIETGIQNTGIAIFLL 395


RESULT 12
ABG64873
ID   ABG64873 standard; Protein; 196 AA.
XX
AC   ABG64873;
XX
DT   27-AUG-2002  (first entry)
XX
DE   Human albumin fusion protein #1548.
XX
KW   Albumin fusion protein; therapeutic protein X; human albumin; HA;
KW   human serum albumin; HSA; cancer; reproductive disorder;
KW   digestive disorder; immune disorder; endocrine disorder;
KW   haematopoietic disorder; neural disorder; connective disorder;
KW   cytostatic; antiinfertility; antiinflammatory; antiulcer;
KW   immunomodulator; anti-HIV; antidiabetic; haemostatic; nootropic;
KW   neuroprotective; antiparkinsonian; antimicrobial; neuroleptic;
KW   osteopathic; antiarthritic.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200177137-A1.
XX
PD   18-OCT-2001.
XX
PF   12-APR-2001; 2001WO-US11988.
XX
PR   12-APR-2000; 2000US-229358P.
PR   25-APR-2000; 2000US-199384P.
PR   21-DEC-2000; 2000US-256931P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Haseltine WA;
XX
DR   WPI; 2002-010886/01.
XX
PT   New fusion protein for treating disease e.g. diabetes comprises an
PT   albumin fused to a therapeutic protein -
XX
PS   Claim 1; Page 1569-1570; 2102pp; English.
XX
CC   The present invention relates to albumin fusion proteins comprising a
CC   therapeutic protein X and human albumin (HA, also known as human serum
CC   albumin, HSA). The proteins are useful for treating a disease or
CC   disorder that may be modulated by therapeutic protein X. The albumin
CC   extends the shelf-life of protein X, and may increase its biological
CC   in vitro/in vivo activity. The protein is useful for treating and
CC   diagnosing disorders such as cancer, reproductive disorders, digestive
CC   disorders (e.g. Crohn's disease, ulcerative colitis), immune disorders
CC   (e.g. acquired immunodeficiency syndrome, AIDS), endocrine disorders
CC   (e.g. diabetes), haematopoietic disorders, neural disorders
CC   (e.g. Alzheimer's, Parkinson's, Creutzfeldt-Jacob disease,
CC   encephalomyelitis, meningitis, schizophrenia), and connective disorders
CC   (e.g. osteoporosis, arthritis). ABG63326-ABG65518 represent albumin
CC   fusion proteins of the invention.
XX
SQ   Sequence   196 AA;

  Query Match             13.4%;  Score 265.5;  DB 23;  Length 196;
  Best Local Similarity   33.0%;  Pred. No. 1.3e-20;
  Matches   59;  Conservative   35;  Mismatches   50;  Indels   35;  Gaps    4;

Qy         119 VDGDMDLSISMTTCSTVAALGMMPLCIYLYTWSW---SLQQNLTIPYQNIGITLVCLTIP 175
               |||||:||| ||  ||: || :||||:::|:|:|    : |   :|   : :||    ||
Db           5 VDGDMNLSIIMTISSTLLALVLMPLCLWIYSWAWINTPIVQ--LLPLGTVTLTLCSTLIP 62

Qy         176 VAFGVYVNYRWPKQSKIILKI---------------GAVVGGVLLLVVAVAGVVLAKGS 219
               :  ||:: |:: : :  |:|:                | ::|  ||  :  |  |:|
Db          63 IGLGVFIRYKYSRVADYIVKVSLWSLLLVTLVVLFIMTGTMLGPELLASIPAAVYVIA--- 119

Qy         220 WNSDITLLTISFIFPLIGHVTGFLLALFTHQSWQRCRTISLETGAQNIQMCITMLQLSF 278
                              || |: :|: ||   |      ||: ||||:||:|:|  :|:|:|
Db         120 -----------IFMPLAGYASGYGLATLFHLPPNCKRTVCLETGSQNVQLCTAILKLAF 167


RESULT 13
AAE21198
ID   AAE21198 standard; Protein; 196 AA.
XX
AC   AAE21198;
```

XX
DT 01-JUL-2002 (first entry)
XX
DE Human gene 8 encoded secreted protein HBCPB32, SEQ ID NO:63.
XX
KW Human; secreted protein; immune disorder; antiallergic; antirheumatic;
KW rheumatoid arthritis; breast neoplasia; breast cancer; antiarthritic;
KW neurological disease; Alzheimer's disease; Parkinson's disease; trauma;
KW Tourette syndrome; encephalitis; cytostatic; haemostatic; anaemia; mania;
KW antiinflammatory; ophthalmalogical; dermatological; immunostimulatory;
KW immunomodulatory; immunosuppressive; antibacterial; antipsoriatic;
KW gene therapy; autoimmune disease; Huntington's disease; meningitis;
KW demyelinating disease; peripheral neuropathy; congenital malformation;
KW spinal cord injury; peripheral neuropathy; ischaemia; perception;
KW multiple sclerosis; infarction; haemorrhage; schizophrenia; dementia;
KW depression; panic disorder; learning disability; ALS; feeding disorder;
KW hyperproliferative disorder; sleep pattern; cardiovascular disorder;
KW reproductive disorder; digestive system disorder; behavioural disorder.

OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Peptide 1..25
FT /label= Signal_peptide
FT Protein 26..95
FT /note= "Human mature secreted protein"
FT Misc-difference 171
FT /label= Unknown
FT /note= "Encoded by YAT"
FT Misc-difference 175
FT /label= Unknown
FT /note= "Encoded by GKA"
FT Misc-difference 177
FT /label= Unknown
FT /note= "Encoded by GKT"
FT Misc-difference 181
FT /label= Unknown
FT /note= "Encoded by GKA"
FT Misc-difference 185
FT /label= Unknown
FT /note= "Encoded by YCA"
FT Misc-difference 188
FT /label= Unknown
FT /note= "Encoded by ARA"
FT Misc-difference 189
FT /label= Unknown
FT /note= "Encoded by ASC"

PN WO200216390-A1.
XX
PD 28-FEB-2002.
XX
PF 17-JAN-2001; 2001WO-US01435.
XX
PR 18-AUG-2000; 2000US-226282P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Komatsoulis GA, Baker KP, Birse CE, Soppet DR, Olsen HS;
PI Moore PA, Wei P, Ebner R, Duan DR, Shi Y, Choi GH, Fiscella M;
PI Ni J;
XX
DR WPI; 2002-304113/34.
DR N-PSDB; AAD33699.
XX
PT An isolated nucleic acid molecule (I) comprising a polynucleotide which
PT encodes a polypeptide useful in the diagnosis and treatment of
PT disorders e.g. immune disorders -
XX
PS Claim 11; Page 477; 534pp; English.
XX
CC AAD33692-AAD33736 represent cDNAs corresponding to 21 human secreted
CC protein genes, and AAE21191-AAE21235 represent the proteins they encode.
CC AAE21236-AAE21280 represent human secreted protein fragments. The genes
CC and their corresponding secreted proteins are useful for preventing,
CC treating or ameliorating medical conditions, e.g., by protein or gene
CC therapy. Pathological conditions can be diagnosed by determining the
CC amount of the new protein in a sample or by determining the presence of
CC mutations in the new genes. Specific uses are described for each of the
CC 21 genes, based on the tissues in which they are most highly expressed,
CC and include developing products for the diagnosis or treatment of
CC immune or autoimmune diseases e.g. AIDS (acquired immune deficiency
CC syndrome), asthma, anaemia and rheumatoid arthritis, breast neoplasia
CC and breast cancer, neurological diseases e.g. Alzheimer's disease,
CC Parkinson's disease, Huntington's disease, Tourette syndrome,
CC meningitis, demyelinating disease, peripheral neuropathies, neoplasia,
CC trauma, congenital malformations, spinal cord injuries, toxic
CC neuropathies induced by neurotoxins, peripheral neuropathies, multiple
CC sclerosis, ischaemia and infarction, haemorrhages, schizophrenia, mania,
CC dementia, depression, panic disorder, learning disabilities, ALS,
CC altered behaviours e.g. disorders in feeding, sleep patterns, balance
CC and perception, encephalitis, disorders in cardiovascular, neural/
CC sensory, reproductive and digestive systems, behavioural disorders and
CC hyperproliferative disorder. The present sequence represents a human
CC secreted protein of the invention.
XX
SQ Sequence 196 AA;

Query Match 13.4%; Score 265.5; DB 23; Length 196;
Best Local Similarity 33.0%; Pred. No. 1.3e-20;
Matches 59; Conservative 35; Mismatches 50; Indels 35; Gaps 4;

```
Qy        119 VDGDMDLSISMTTCSTVAALGMMPLCIYLYTWSW---SLQQNLTIPYQNIGITLVCLTIP 175
              |||||:|||  ||  ||: || :||||:::|:|:|    : |   :|   : :||    ||
Db          5 VDGDMNLSIIMTISSTLLALVLMPLCLWIYSWAWINTPIVQ--LLPLGTVTLTLCSTLIP 62

Qy        176 VAFGVYVNYRWPKQSKIILKI----------------GAVVGGVLLLVVAVAGVVLAKGS 219
              :  ||:: |:: : :  |:|:                | ::|  ||  :  |  |:|
Db         63 IGLGVFIRYKYSRVADYIVKVSLWSLLVTLVVLFIMTGTMLGPELLASIPAAVYVIA--- 119

Qy        220 WNSDITLLTISFIPPLIGHVTGPLLALFTHQSWQRCRTISLETGAQNIQMCITMLQLSF 278
                          || |: :|: ||   |      ||: ||||:||:|:|  :|:|:|
Db        120 -----------IFMPLAGYASGYGLATLFHLPPNCKRTVCLETGSQNVQLCTAILKLAF 167
```

RESULT 14
AAG92300
ID AAG92300 standard; Protein; 324 AA.
XX
AC AAG92300;
XX
DT 26-SEP-2001 (first entry)
XX
DE C glutamicum protein fragment SEQ ID NO: 6054.
XX
KW Coryneform bacterium; amino acid synthesis; vitamin; saccharide;
KW organic acid synthesis.
XX
OS Corynebacterium glutamicum.
XX
PN EP1108790-A2.
XX
PD 20-JUN-2001.
XX
PF 18-DEC-2000; 2000EP-0127688.
XX
PR 16-DEC-1999; 99JP-0377484.
PR 07-APR-2000; 2000JP-0159162.
PR 03-AUG-2000; 2000JP-0280988.
XX
PA (KYOW) KYOWA HAKKO KOGYO KK.
XX
PI Nakagawa S, Mizoguchi H, Ando S, Hayashi M, Ochiai K, Yokoi H;
PI Tateishi N, Senoh A, Ikeda M, Ozaki A;
XX
DR WPI; 2001-376931/40.

```
DR   N-PSDB; AAH67519.
XX
PT   Novel polynucleotides derived from Coryneform bacteria, for identifying
PT   mutation point of a gene, measuring expression of a gene, analysing
PT   expression profile or pattern of a gene and identifying homologous gene
PT   -
XX
PS   Claim 17; SEQ ID NO: 6054; 246pp + Sequence Listing; English.
XX
CC   The present invention provides a number of nucleotide and protein
CC   sequences from the Coryneform bacterium Corynebacterium glutamicum. These
CC   are useful for identifying the mutation point of a gene derived from a
CC   mutant of coryneform bacterium, measuring expression amount and
CC   analysing the expression profile or expression pattern of a gene derived
CC   from Coryneform bacterium, and identifying a homologue of a gene derived
CC   from coryneform bacterium. Coryneform bacteria are useful for producing
CC   amino acids, nucleic acids, vitamins, saccharides and organic acids,
CC   particularly L-lysine. The present sequence is a protein described
CC   in the exemplification of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
     specification, but was obtained in electronic format directly from the
     European Patent Office.

SQ   Sequence   324 AA;

  Query Match            13.4%;  Score 264.5;  DB 22;  Length 324;
  Best Local Similarity  25.6%;  Pred. No. 3.3e-20;
  Matches   66;  Conservative   66;  Mismatches   91;  Indels   35;  Gaps    6;

Qy         40 VMMGLLMFSLGCSVEIRKLWSHIRRPWGIAVGLLCQFGLMPFTAYLLAISFSLKPVQAIA 99
Db         44 IFLTIIMFTMGLTLTVPDFQMVLKRPLPILIGVVAQFVIMPFLAIVVAKMFNLNPALAVG 103

Qy        100 VLIMGCCPGGTISNIFTFWVDGDMDLSISMTTCSTVAALGMMPLCIYLYT---------- 149
Db        104 LLMLGSVPGGTSSNVIAFLARGDVALSVTMTSVSTIVSPIMTPFLMLMLAGTETAVDGGG 163

Qy        150 WSWSLQQNLTIPYQNIGITLVCLTIPVAFGVYVNYRWPKQSKIILKIGAVVGGVLLLVVA 209
Db        164 MAWTLVQTVLLP----------VIIGLVLRVFLN-KWIDKILPILPYLSILG-------- 204

Qy        210 VAGVVLAKGSWNSD--ITLLTISFIFPLIGHVTGFLLALFTHQSWQ----RCRTISLETG 263
Db        205 IGGVVFGAVAANAERLVSVGLIVFVAVIVHNVLGYVVGYLTGRVFKFPEAANRTMAIEIG 264

Qy        264 AQNIQMCITMLQLSFTAE 281
Db        265 TQSAGLASGMAGRFFTPE 282
```

[redacted]SULT 15
AAG22454
```
ID   AAG22454 standard; Protein; 271 AA.
XX
AC   AAG22454;
XX
DT   17-OCT-2000  (first entry)
XX
DE   Arabidopsis thaliana protein fragment SEQ ID NO: 25388.
XX
KW   Protein identification; signal transduction pathway; metabolic pathway;
KW   hybridisation assay; genetic mapping; gene expression control; promoter;
KW   termination sequence.
XX
OS   Arabidopsis thaliana.
XX
PN   EP1033405-A2.
XX
PD   06-SEP-2000.
XX
PF   25-FEB-2000; 2000EP-0301439.
XX
PR   25-FEB-1999;   99US-0121825.
PR   05-MAR-1999;   99US-0123180.
PR   09-MAR-1999;   99US-0123548.
PR   23-MAR-1999;   99US-0125788.
PR   25-MAR-1999;   99US-0126264.
PR   29-MAR-1999;   99US-0126785.
PR   01-APR-1999;   99US-0127462.
PR   06-APR-1999;   99US-0128234.
PR   08-APR-1999;   99US-0128714.
PR   16-APR-1999;   99US-0129845.
PR   19-APR-1999;   99US-0130077.
PR   21-APR-1999;   99US-0130449.
PR   23-APR-1999;   99US-0130510.
PR   23-APR-1999;   99US-0130891.
PR   28-APR-1999;   99US-0131449.
PR   30-APR-1999;   99US-0132048.
PR   30-APR-1999;   99US-0132407.
PR   04-MAY-1999;   99US-0132484.
PR   05-MAY-1999;   99US-0132485.
PR   06-MAY-1999;   99US-0132486.
PR   06-MAY-1999;   99US-0132487.
PR   07-MAY-1999;   99US-0132863.
PR   11-MAY-1999;   99US-0134256.
PR   14-MAY-1999;   99US-0134218.
PR   14-MAY-1999;   99US-0134219.
PR   14-MAY-1999;   99US-0134221.
PR   14-MAY-1999;   99US-0134370.
PR   18-MAY-1999;   99US-0134768.
PR   19-MAY-1999;   99US-0134941.
PR   20-MAY-1999;   99US-0135124.
PR   21-MAY-1999;   99US-0135353.
PR   24-MAY-1999;   99US-0135629.
PR   25-MAY-1999;   99US-0136021.
PR   27-MAY-1999;   99US-0136392.
PR   28-MAY-1999;   99US-0136782.
PR   01-JUN-1999;   99US-0137222.
PR   03-JUN-1999;   99US-0137528.
PR   04-JUN-1999;   99US-0137502.
PR   07-JUN-1999;   99US-0137724.
PR   08-JUN-1999;   99US-0138094.
PR   10-JUN-1999;   99US-0138540.
PR   10-JUN-1999;   99US-0138847.
PR   14-JUN-1999;   99US-0139119.
PR   16-JUN-1999;   99US-0139452.
PR   16-JUN-1999;   99US-0139453.
PR   17-JUN-1999;   99US-0139492.
PR   18-JUN-1999;   99US-0139454.
PR   18-JUN-1999;   99US-0139455.
PR   18-JUN-1999;   99US-0139456.
PR   18-JUN-1999;   99US-0139457.
PR   18-JUN-1999;   99US-0139458.
PR   18-JUN-1999;   99US-0139459.
PR   18-JUN-1999;   99US-0139460.
PR   18-JUN-1999;   99US-0139461.
PR   18-JUN-1999;   99US-0139462.
PR   18-JUN-1999;   99US-0139463.
PR   18-JUN-1999;   99US-0139750.
PR   18-JUN-1999;   99US-0139763.
PR   21-JUN-1999;   99US-0139817.
PR   22-JUN-1999;   99US-0139899.
PR   23-JUN-1999;   99US-0140353.
PR   23-JUN-1999;   99US-0140354.
PR   24-JUN-1999;   99US-0140695.
PR   28-JUN-1999;   99US-0140823.
PR   29-JUN-1999;   99US-0140991.
PR   30-JUN-1999;   99US-0141287.
PR   01-JUL-1999;   99US-0141842.
PR   01-JUL-1999;   99US-0142154.
PR   02-JUL-1999;   99US-0142055.
PR   06-JUL-1999;   99US-0142390.
PR   08-JUL-1999;   99US-0142803.
PR   09-JUL-1999;   99US-0142920.
PR   12-JUL-1999;   99US-0142977.
PR   13-JUL-1999;   99US-0143542.
```

PR 14-JUL-1999; 99US-0143624.
PR 15-JUL-1999; 99US-0144005.
PR 16-JUL-1999; 99US-0144085.
PR 16-JUL-1999; 99US-0144086.
PR 19-JUL-1999; 99US-0144325.
PR 19-JUL-1999; 99US-0144331.
PR 19-JUL-1999; 99US-0144332.
PR 19-JUL-1999; 99US-0144333.
PR 19-JUL-1999; 99US-0144334.
PR 19-JUL-1999; 99US-0144335.
PR 20-JUL-1999; 99US-0144352.
PR 20-JUL-1999; 99US-0144632.
PR 20-JUL-1999; 99US-0144884.
PR 21-JUL-1999; 99US-0144814.
PR 21-JUL-1999; 99US-0145086.
PR 21-JUL-1999; 99US-0145088.
PR 22-JUL-1999; 99US-0145085.
22-JUL-1999; 99US-0145087.
22-JUL-1999; 99US-0145089.
22-JUL-1999; 99US-0145192.
PR 23-JUL-1999; 99US-0145145.
PR 23-JUL-1999; 99US-0145218.
PR 23-JUL-1999; 99US-0145224.
PR 26-JUL-1999; 99US-0145276.
PR 27-JUL-1999; 99US-0145913.
PR 27-JUL-1999; 99US-0145918.
PR 27-JUL-1999; 99US-0145919.
PR 28-JUL-1999; 99US-0145951.
PR 02-AUG-1999; 99US-0146386.
PR 02-AUG-1999; 99US-0146388.
PR 02-AUG-1999; 99US-0146389.
PR 03-AUG-1999; 99US-0147038.
PR 04-AUG-1999; 99US-0147204.
PR 04-AUG-1999; 99US-0147302.
PR 05-AUG-1999; 99US-0147192.
PR 05-AUG-1999; 99US-0147260.
PR 06-AUG-1999; 99US-0147303.
PR 06-AUG-1999; 99US-0147416.
PR 09-AUG-1999; 99US-0147493.
PR 09-AUG-1999; 99US-0147935.
PR 10-AUG-1999; 99US-0148171.
PR 11-AUG-1999; 99US-0148319.
PR 12-AUG-1999; 99US-0148341.
PR 13-AUG-1999; 99US-0148565.
PR 13-AUG-1999; 99US-0148684.
16-AUG-1999; 99US-0149368.
17-AUG-1999; 99US-0149175.
18-AUG-1999; 99US-0149426.
PR 20-AUG-1999; 99US-0149722.
PR 20-AUG-1999; 99US-0149723.
PR 20-AUG-1999; 99US-0149929.
PR 23-AUG-1999; 99US-0149902.
PR 23-AUG-1999; 99US-0149930.
PR 25-AUG-1999; 99US-0150566.
PR 26-AUG-1999; 99US-0150884.
PR 27-AUG-1999; 99US-0151065.
PR 27-AUG-1999; 99US-0151066.
PR 27-AUG-1999; 99US-0151080.
PR 30-AUG-1999; 99US-0151303.
PR 31-AUG-1999; 99US-0151438.
PR 01-SEP-1999; 99US-0151930.
PR 07-SEP-1999; 99US-0152363.
PR 10-SEP-1999; 99US-0153070.
PR 13-SEP-1999; 99US-0153758.
PR 15-SEP-1999; 99US-0154018.
PR 16-SEP-1999; 99US-0154039.
PR 20-SEP-1999; 99US-0154779.
PR 22-SEP-1999; 99US-0155139.
PR 23-SEP-1999; 99US-0155486.
PR 24-SEP-1999; 99US-0155659.
PR 28-SEP-1999; 99US-0156458.
PR 29-SEP-1999; 99US-0156596.
PR 04-OCT-1999; 99US-0157117.
PR 05-OCT-1999; 99US-0157753.
PR 06-OCT-1999; 99US-0157865.
PR 07-OCT-1999; 99US-0158029.
PR 08-OCT-1999; 99US-0158232.
PR 12-OCT-1999; 99US-0158369.
PR 13-OCT-1999; 99US-0159293.
PR 13-OCT-1999; 99US-0159294.
PR 13-OCT-1999; 99US-0159295.
PR 14-OCT-1999; 99US-0159329.
PR 14-OCT-1999; 99US-0159330.
PR 14-OCT-1999; 99US-0159331.
PR 14-OCT-1999; 99US-0159637.
PR 14-OCT-1999; 99US-0159638.
PR 18-OCT-1999; 99US-0159584.
PR 21-OCT-1999; 99US-0160741.
PR 21-OCT-1999; 99US-0160767.
PR 21-OCT-1999; 99US-0160768.
PR 21-OCT-1999; 99US-0160770.
PR 21-OCT-1999; 99US-0160814.
PR 21-OCT-1999; 99US-0160815.
PR 22-OCT-1999; 99US-0160980.
PR 22-OCT-1999; 99US-0160981.
PR 22-OCT-1999; 99US-0160989.
PR 25-OCT-1999; 99US-0161404.
PR 25-OCT-1999; 99US-0161405.
PR 25-OCT-1999; 99US-0161406.
PR 26-OCT-1999; 99US-0161359.
PR 26-OCT-1999; 99US-0161360.
PR 26-OCT-1999; 99US-0161361.
PR 28-OCT-1999; 99US-0161920.
PR 28-OCT-1999; 99US-0161992.
PR 28-OCT-1999; 99US-0161993.
PR 29-OCT-1999; 99US-0162142.

Query Match 13.3%; Score 264; DB 21; Length 271;
Best Local Similarity 27.1%; Pred. No. 2.9e-20;
Matches 67; Conservative 47; Mismatches 103; Indels 30; Gaps 6;

```
Qy         46 MFSLGCSVEIRKLWSHIRRPWGIAVGLLCQFGLMPFTAYLLAISFSLKPVQAIAVLIMGC 105
              | |:| ::        :| || : || | |: : |   :|:|::  |    |  :::: |
Db          1 MLSMGLTLTFEDFRRCLRNPWTVGVGFLAQYMIKPILGFLIAMTLKLSAPLATGLILVSC 60

Qy        106 CPGGTISNIFTFWVDGDMDLSISMTTCSTVAALGMMPLCIYLYTWSWSLQQNLTIPYQNI 165
              ||||  ||: |:   |:: ||: |||||: |: | ||          |     :|
Db         61 CPGGQASNVATYISKGNVALSVLMTTCSTIGAIIMTPLLT-------KLLAGQLVPVDAA 113

Qy        166 GI---TLVCLTIPVAFGVYVNYRWPKQSKIILKIGAVVGGVLLLVVA------VAGVVLA 216
              |:   |   : :|   ||  |  :|| :  |: :  ::| :|  ::       || |:
Db        114 GLALSTFQVVLVPTIIGVLANEFFPKFTSKIITVTPLIGVILTTLLCASPIGQVADVLKT 173

Qy        217 KGSWNSDITLLTISFIFPL-IGHVTGFLLALFTHQ---SWQRCRTISLETGAQNIQMCIT 272
              :|:           | |: : |   | :  :  :        ||||:| | |:  :
Db        174 QGA----------QLILPVALLHAAAFAIGYWISKFSFGESTSRTISIECGMQSSALGFL 223

Qy        273 MLQLSFT 279
              : |  ||
Db        224 LAQKHFT 230
```

Search completed: June 9, 2003, 07:08:08
Job time : 44 secs